COECSA, Journal, Ophthalmology
Branch retinal vein occlusions: a review
Download PDF Article

Keywords

Branch retinal vein occlusion
Laser
Steroids
AntiVEGFS
Macular oedema

Categories

How to Cite

Gachago MM, Kibata AG. (2023). Branch retinal vein occlusions: a review. The Journal of Ophthalmology of Eastern, Central and Southern Africa, 15(01). Retrieved from https://joecsa.coecsa.org/index.php/joecsa/article/view/259

Abstract

Introduction: Branch Retinal Vein Occlusion (BRVO) is the second most common retinal vascular disease with a
prevalence of 0.8%. The Branch Vein Occlusion Study was the first trial to show efficacy of treatment of macular
oedema in BRVO with grid laser which was considered the gold standard for several years. Since then several
other studies have been done on various classes of drugs and surgery and there are great strides that have
been made in enhancing the visual and anatomical outcome. In this review article, we did a pubmed search of
publications done over the years on the natural history of BRVO as well as the treatment options. The studies
included clinical trials, systematic reviews and case reports.

Results: Currently anti-Vascular Endothelial Growth Factors (AntiVEGFs) appear to have the best outcomes in
terms of anatomical and visual recovery. Other therapies that have shown promise are the intravitreal steroids,
grid laser, antiVEGFs and steroids combined with lasers. Parsplana vitrectomy appears to be as efficacious as
antiVEGF but is very invasive and no good clinical trials have been done yet.

Conclusion: Great strides have been made in improving the outcome of BRVO especially the macular oedema if
prompt and correct treatment is administered to the patient.

Download PDF Article

References

Lam FC, Chia SN, Lee RM. Macular grid laser

photocoagulation for branch retinal vein occlusion.

Cochrane Database Syst Rev. 2015; 5:CD008732.

Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj

N, Rundle AC, et al. Ranibizumab for macular

edema following branch retinal vein occlusion: Sixmonth

primary end point results of a phase III study.

Ophthalmology. 2010; 117(6):1102-12.

Rehak, J. Branch retinal vein occlusion: pathogenesis,

visual prognosis, and treatment modalities. Curr Eye

Res. 2008; 33(2): 111–131.

Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of

plasma homocysteine, serum folate, serum vitamin

B12, and thermolabile MTHFR genotype as risk

factors for retinal vascular occlusive disease. Am J

Ophthalmol. 2003; 136(6):1136–1150.

Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N,

et al. Natural history of branch retinal vein occlusion:

an evidence-based systematic review. Ophthalmology.

; 117: 1094–1101. [PubMed: 20430447]

Hayreh S. Ocular vascular occlusive disorders:

Natural history of visual outcome. Prog Retin Eye

Res. 2014; 4: 1–25.

Hayreh S, Zimmerman B. Fundus changes in branch

retinal vein occlusion. Retina. 2015; 35(5):1016–1027

The Branch Vein Occlusion Study Group: Argon laser

photocoagulation for macular edema in branch vein

occlusion. Am J Ophthalmol. 1984; 98(3):271-282.

Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi

BA, Fisher M, et al. A randomized trial comparing

the efficacy and safety of intravitreal triamcinolone

with standard care to treat vision loss associated

with macular edema secondary to branch retinal vein

occlusion: The Standard Care vs Corticosteroid for

Retinal Vein Occlusion (SCORE) study report 6.

Arch Ophthalmol. 2009; 127(9):1115-28.

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS,

Gillies M, et al. Dexamethasone intravitreal implant

in patients with macular edema related to branch or

central retinal vein occlusion twelve-month study

results. Ophthalmology. 2011; 118(12):2453-60.

Hikichi T, Higuchi M, Matsushita T, Kosaka S,

Matsushita R, Takami K, et al. Two-year outcomes of

intravitreal bevacizumab therapy for macular oedema

secondary to branch retinal vein occlusion. Br J

Ophthalmol. 2014; 98(2):195-199.

Rush RB, Simunovic MP, Aragon AV, Ysasaga JE.

Treat-and-extend intravitreal bevacizumab for branch

retinal vein occlusion. Ophthalmic Surg Lasers

Imaging Retina. 2014; 45(3):212-216.

Guignier B, Subilia-Guignier A, Fournier I, Ballonzoli

L, Speeg-Schatz C, Gaucher D. Prospective pilot

study: Efficacy of intravitreal dexamethasone and

bevacizumab injections in the treatment of macular

oedema associated with branch retinal vein occlusion.

Ophthalmologica. 2013; 230(1):43-49.

Leitritz MA, Gelisken F, Ziemssen F, Szurman P, Bartz-

Schmidt KU, Jaissle GB. Grid laser photocoagulation

for macular oedema due to branch retinal vein

occlusion in the age of bevacizumab? Results of

a prospective study with crossover design. Br J

Ophthalmol. 2013; 97(2):215-219.

Brown DM, Campochiaro PA, Bhisitkul RB, Ho

AC, Gray S, Saroj N, et al. Sustained benefits from

ranibizumab for macular edema following branch

retinal vein occlusion: 12-month outcomes of a phase

III study. Ophthalmology. 2011; 118(8):1594-1602.

Campochiaro PA, Clark WL, Boyer DS, Heier JS,

Brown DM, Vitti R, et al. Intravitreal aflibercept

for macular edema following branch retinal vein

occlusion: The 24-week results of the VIBRANT

study. Ophthalmology. 2015; 122(3):538-544.

Clark WL, Boyer DS, Heier JS, Brown DM, Haller

JA, Vitti R, et al. Intravitreal aflibercept for macular

edema following branch retinal vein occlusion: 52-

week results of the VIBRANT study. Ophthalmology.

; 123(2):330-336.

Houtsmuller JA, Vermeulen M. Klompe, et al. The

influence of ticlopidine on the natural course of

retinal vein occlusion. Agents Actions Suppl. 1984;

: 219-229.

Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A,

Lelong F, Samama MM. A randomized, doublemasked

study on the treatment of retinal vein

occlusion with troxerutin. Amer J Ophthalmol. 1994;

(4): 421-429.

Murakami T, Takagi H, Kita M, et al. Intravitreal

tissue plasminogen activator to treat macular edema

associated with branch retinal vein occlusion. Amer J

Ophthalmol. 2006; 142(2): 318-320.

Hattenbach LO, Steinkamp G, Scharrer I, Ohrloff

C. Fibrinolytic therapy with low dose recombinant

tissue plasminogen activator in retinal vein occlusion.

Ophthalmologica. 1998; 212(6): 394-398.

Lazo-Langner A, Hawel J, Ageno W, Kovacs MJ.

Low molecular weight heparin for the treatment of

retinal vein occlusion: a systematic review and metaanalysis

of randomized trials. Haematologica. 2010;

(9): 1587–1593.

Ageno W, Cattaneo R, Manfredi E, et al. Parnaparin

versus aspirin in the treatment of retinal vein

occlusion. A randomized, double blind, controlled

study. Thrombosis Res. 2010; 125(2): 137–141.

Tomomatsu Y, Tomomatsu T, Takamura Y, Gozawa M,

Arimura S, Takihara Y, et al. Comparative study of

combined bevacizumab/targeted photocoagulation vs

bevacizumab alone for macular oedema in ischaemic

branch retinal vein occlusions. Acta Ophthalmol.

; 94(6): e225-230.

Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon

S, Zimmer-Galler I, et al. Scatter photocoagulation

does not reduce macular edema or treatment burden

in patients with retinal vein occlusion: The RELATE

Trial. Ophthalmology. 2015; 122(7):1426-1437.

Pielen A, Mirshahi A, Feltgen N, Lorenz K, Korb

C, Junker B, et al. Ranibizumab for Branch Retinal

Vein Occlusion Associated Macular Edema Study

(RABAMES): Six-month results of a prospective

randomized clinical trial. Acta Ophthalmol. 2015;

(1):e29.

Azad SV, Salman A, Mahajan D, Sain S, Azad R.

Comparative evaluation between ranibizumab

combined with laser and bevacizumab combined

with laser versus laser alone for macular oedema

secondary to branch retinal vein occlusion. Middle

East Afr J Ophthalmol. 2014; 21(4):296-301.

Lam FC, Chia SN, Lee RM. Macular grid laser

photocoagulation for branch retinal vein occlusion.

Cochrane Database Syst Rev. 2015; 5:CD008732.

Adelman RA, Parnes AJ, Bopp S, Saad Othman I,

Ducournau D. Strategy for the management of macular

edema in retinal vein occlusion: The European Vitreo

Retinal Society Macular Edema study. Biomed Res

Int. 2015; 2015:870987

Downloads

Download data is not yet available.